NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates
Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand its oncology pipeline Sutro’s Xpress CF+™ platforms to be utilized to develop...
Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member
Collaboration to Express Antibodies and Antigens based on Sutro’s Technology Platform XpressCF+™ SAN FRANCISCO, Sept. 9, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug...
Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference
SAN FRANCISCO, Mar. 24, 2014 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21st Annual...
Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
SAN FRANCISCO, Jan. 07, 2014 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration...
Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
SAN FRANCISCO, Dec. 11, 2013 - Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of Sutro’s proprietary immuno-oncology product pipeline. Sutro is developing a new...
Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
SAN FRANCISCO, Jan. 31, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment...
Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
SAN FRANCISCO, Jan. 3, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced a collaboration with Sanofi Pasteur -- the largest company entirely...
Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies
SAN FRANCISCO, Dec. 18, 2012 - Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody....
Sutro Biopharma Expands Senior Management Team Jeremy Bender, Ph.D., Joins as Chief Business Officer; Aaron K. Sato, Ph.D., Named Vice President, Research
SAN FRANCISCO, October 24, 2012 - Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, today announced the expansion of its senior...
Sutro Closes $16.5 Million Second Tranche of Series C Financing
SAN FRANCISCO, May 8, 2012 - Sutro Biopharma today announced the closing of the $16.5 million second tranche of its Series C financing. This financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta...
